MT-1 (Afamelanotide/Melanotan I) is a synthetic 13-amino acid analog of alpha-MSH that stimulates melanin production through the MC1R receptor. It was developed at the University of Arizona.

How does MT-1 differ from MT-2?

MT-1 is a linear peptide with a more selective receptor profile focused on MC1R and melanogenesis. MT-2 is a cyclic peptide with broader receptor activity including effects on sexual function and appetite.

How should MT-1 be stored?

Lyophilized MT-1 should be stored below -18°C, away from light and moisture. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 7 days.

Has MT-1 been approved anywhere?

Yes. The European Medicines Agency approved Afamelanotide for the treatment of otoporphyria. Research-grade product is not equivalent to the approved formulation.

Is MT-1 FDA approved?

No. MT-1 is not FDA approved. It has EMA approval for a specific rare disease. Research-grade product is sold for laboratory purposes only.

-25%

4X Tested - ISO 17025

99.80% View COA

Melanocortin Peptide

MT-1 Nasal

Certificate of Analysis

MT-1 (Afamelanotide) is a synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (α-MSH), studied for its effects on melanogenesis and photoprotection in preclinical and clinical research.

Size

Clear

BUNDLE & SAVE

1 Bottle $44.99 MOST POPULAR

2 Bottles $86.84

3+ Bottles $128.22

2-Day Shipping

Free Shipping
over $200

Free shipment
protection

Secure Checkout
256-bit SSL

Description

What is MT-1 Nasal?

MT-1, also known as Afamelanotide or Melanotan I, is a synthetic linear analog of alpha-melanocyte-stimulating hormone (α-MSH). It consists of 13 amino acids and was developed to be a more potent and longer-lasting version of the natural hormone.

MT-1 acts primarily on the melanocortin 1 receptor (MC1R) to stimulate melanogenesis, the production of melanin pigment in the skin. Unlike its cyclic counterpart MT-2, it has a more selective receptor profile and has been studied specifically for photoprotective applications.

Afamelanotide has been approved by the European Medicines Agency (EMA) under the brand name Scenesse for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare genetic condition causing severe light sensitivity.

Research-grade MT-1 is not equivalent to approved formulations and is sold strictly for laboratory and research purposes only.

Research Applications

Areas of Investigation

Pigmentation

Melanogenesis & Pigmentation

Studied for its ability to stimulate melanin production through MC1R activation, increasing skin pigmentation.

UV Protection

Photoprotection

Investigated and EMA-approved for preventing phototoxicity in patients with erythropoietic protoporphyria (EPP).

DNA Repair

DNA Repair Research

Explored for its potential to enhance DNA repair mechanisms in UV-damaged skin cells through melanocortin signaling.

Skin Health

Skin Condition Research

Studied in clinical trials for vitiligo and polymorphous light eruption for its ability to modulate skin pigmentation.

Compound Profile

Technical specifications

What is MT-1 Nasal?

Molecular Profile

Sequence

Ac-SYS-n-EH-f RWGKPV-NH₂

Molecular Formula

C₇₈H₁₁₁N₂₁O₁₉

Molecular Weight

1,646.85 g/mol

Appearance

White lyophilized powder

Form

Lyophilized (freeze-dried)

Handling & Shelf Life Guidelines

Storage & Stability

Storage (Pre-Reconstitution)

Store below -18°C, desiccated, away from light and moisture.

Storage (Post-Reconstitution)

Refrigerate at 2–8°C. For longer storage, aliquot and store below -18°C. Avoid freeze-thaw cycles.

Shelf Life

24 months from date of manufacture when stored as directed

Sensitivity Notes

Sensitive to heat, light, and moisture. Keep sealed until use.

Compliance & Clinical Overview

Regulatory & Research Status

FDA Status

Not FDA approved. EMA-approved as Scenesse for erythropoietic protoporphyria (EPP). Research-grade product is not equivalent.

WADA Classification

Not currently specifically listed (MT-2 is prohibited; MT-1 status varies by jurisdiction).

Clinical Trial Status

Clinical and preclinical studies covering melanogenesis, photoprotection, DNA repair mechanisms, and skin pigmentation.

Published Studies

Clinical and preclinical studies covering melanogenesis, photoprotection, DNA repair mechanisms, and skin pigmentation.

Research Disclaimer

For laboratory and research purposes only. Not intended for human consumption.

COA's (Certificate of Analysis)

Third Party Tested by Freedom Diagnostics

99.80%

Purity

Variant

Melanotan I

Lot #

GL-2609-029

Labelled

10mg

Actual

10.47mg

Tested

9/14/2026

View COA

(opens in a new tab)

99.47%